InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.039 0.007 (21.88%)+
Announcement
Release
20 May 2026 9:31AM
Price at Release
$0.032
Full Release
download
Summary
Patrys Limited has advanced its RLS-2202 program towards a Phase 1A clinical trial by appointing CMAX as the trial site and Alithia Life Sciences as the Contract Research Organisation (CRO). These appointments are key milestones for the company as they prepare for the clinical-stage development of RLS-2202, an injectable formulation of Quetiapine designed for treating delirium in acute care settings. The trial is set to begin dosing in Q3 2026, subject to human research ethics committee approval. These developments align with Patrys' strategy to leverage existing clinical data under the FDA 505(b)(2) regulatory pathway, supporting the generation of new data specific to the RLS-2202 formulation.
Key Points
  • Patrys appoints CMAX as Phase 1A clinical trial site.
  • Alithia Life Sciences appointed as CRO.
  • Phase 1A study to assess safety, tolerability, and pharmacokinetics.
  • Trial set to commence in Q3 2026 pending approvals.
  • RLS-2202 targets delirium treatment in acute care settings.
  • Program to pursue FDA 505(b)(2) regulatory pathway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.